The next-generation sutureless surgical technology is based on a clinically proven platform and designed for valve durability Perceval Plus is the next generation of Perceval, which is a trusted ...

PERSIST-AVR study results presented at American Association for Thoracic Surgery Annual Meeting PERSIST-AVR is the first prospective, randomized, multi-center international trial comparing Perceval ...

LONDON--(BUSINESS WIRE)-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced its Perceval ® sutureless aortic heart valve received ...

LivaNova, PLC (the “Company”), a global medical technology company and a leader in the treatment of cardiovascular diseases, announced the first U.S. implantation of the Perceval valve, the sutureless ...

LivaNova is launching the Perceval Plus sutureless surgical aortic heart valve in Europe. The news comes after the company completed a one-year limited launch with initial real-world clinical data ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

A newly described small molecule inhibitor called AOH-1996 targets a cancer-associated isoform of PCNA (caPCNA), leading to a very broad therapeutic window.

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced that the advanced Perceval ® Plus sutureless surgical aortic heart valve ...

LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, presented the first data from the Perceval ® Sutureless Implant Versus Standard-Aortic ...